Sarepta Pauses Elevidys for Older Duchenne Patients After Second Liver-Related Death

Published on The Associated Press

Sarepta has suspended shipments of Elevidys and paused a trial arm after a second non-ambulatory teenage patient died due to acute liver injury. Both cases involved older adolescents receiving higher doses. The company is convening an expert panel to tighten safety measures and plans increased use of immunosuppression. These events have led to a 40+ percent drop in Sarepta’s share price. The FDA is reviewing the therapy’s risk profile and may limit its use in older patients. Elevidys, approved in 2023 under accelerated review, remains available to ambulatory kids. Read the full article from AP News

👉 Second patient death reported with gene therapy for muscular dystrophy

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.